Slam BioTherapeutics

Executive Summary

SLAM BioTherapeutics is a private, next-generation oncology company developing first-in-class antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the SLAM family of immune receptors. Founded in 2021 and headquartered in Cambridge, MA, the company leverages a novel platform to address high unmet need in hematologic malignancies. Its lead program is in Phase 1/2 clinical development for difficult-to-treat blood cancers, aiming to demonstrate safety and early efficacy. The SLAM family represents a validated but underexploited target class, offering potential for differentiated therapies with improved therapeutic indices. The company is at an early clinical stage with no disclosed funding amounts, but its focus on SLAM-directed ADCs and bispecifics positions it in a competitive oncology landscape. Upcoming catalysts include initial clinical data from its lead program, potential partnership discussions, and series B financing to support pipeline expansion. While early-stage risk is high, the novelty of the platform and unmet need in hematologic malignancies provide a compelling rationale for continued development.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data readout for lead ADC program80% success
• Q2 2027Strategic partnership or co-development agreement40% success
• Q3 2026Series B financing round50% success